TP53 and cancer: In this study, we found that the reduction in the TIGAR after a combined treatment of p53 and cisplatin altered the metabolic pattern of the tumor cells, and the PPP was inhibited, which is critical for cancer therapy, as a high PPP flux may make cancer cells exhibit a stronger phenotype in terms of proliferation, invasion, and drug resistance.